Zynex Inc (ZYXI) 0.1500 $ZYXI Zynex Announces Second

New Post Public Reply Private Reply Replies (0) Message Board

Sep 12, 2015 at 8:43 AM

Zynex Inc (ZYXI) 0.1500 $ZYXI

Zynex Announces Second Quarter 2015 Results
Marketwired - Thu Aug 13, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neuro diagnostics, cardiac monitoring and compound pharmacy, announced today its second quarter 2015 financial results.

Zynex Schedules Second Quarter 2015 Earnings Release and Webcast
ACCESSWIRE - Thu Aug 06, 7:01AM CDT
LONE TREE, CO / ACCESSWIRE / August 6, 2015 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it will host the Company's second quarter investor webcast on Thursday, August 13, 2015 at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time.)

Zynex passes DMEPROS programme accreditation upon meeting strict quality, integrity and effectiveness standards
M2 - Thu Jul 02, 8:19AM CDT
Zynex (OtherOTC:ZYXI) revealed on Wednesday that it has received accreditation for its Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) programme from the Accreditation Commission for Health Care.

Zynex Receives DMEPROS Program Accreditation
PRWeb - Wed Jul 01, 8:05AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today it has been awarded accreditation for its Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) program from the Accreditation Commission for Health Care.

Zynex updates Q2 2015 revenue in USD3.2m to USD3.5m range
M2 - Mon Jun 15, 4:43AM CDT
Medical technology company Zynex (OtherOTC:ZYXI) said on Friday that it expects its revenue to be in the range of USD3.2m to USD3.5m for the second quarter ending 30 June 2015.

Zynex Receives Response from FDA on Blood Volume Monitor
GlobeNewswire - Fri Jun 12, 11:22AM CDT
via PRWEB - Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today it has received a response from the FDA concerning the basis for filing its application for approval of its new Blood Volume Monitor. As such, the Company has begun to prepare its request for approval pursuant to Section 510(k) of the Food, Drug and Cosmetic Act.

Zynex Provides Updated Guidance for the Second Quarter 2015
GlobeNewswire - Fri Jun 12, 8:07AM CDT
via PRWEB - Zynex, Inc. (OTCQB:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today it currently expects revenue for the quarter ending June 30, 2015 to be higher than revenue reported in the first quarter of 2015 and be in the range of $3.2 million to $3.5 million. The lower estimate is primarily the result of notification from TRICARE, the health care program for uniformed service members, that it would no longer accept claims related to compound transdermal pain creams.

WEALTHMAKERS.COM: Zynex, Inc. (ZYXI) is Undervalued With Short Term Bullish Patterns and Pending Short Squeeze
M2 - Thu May 21, 10:18AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has initiated coverage today on Zynex Inc. (OTC: ZYXI). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $0.659 and the projected short squeeze valuation of $0.86 per share.

Zynex Receives 44th Pharmacy License Approval
GlobeNewswire - Thu May 21, 7:33AM CDT
via PRWEB - Zynex, Inc. (OTCQB:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it has received license approval from the State of Arkansas for its compound pharmacy business Pharmazy. This brings to 44 the total states, including the District of Columbia, in which the Company is licensed to provide compound pharmacy services.

Zynex Retains BUYINS.NET to Surveil Market Maker and Short Sellers
PRWeb - Tue May 19, 8:10AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics and compound pharmacy, announced today it has retained Buyins.net to initiate coverage and compliance monitoring, short sale trading statistics and market integrity surveillance on its stock. Buyins.net monitors ZYXI market-makers daily for compliance with Fair Market-Making Requirements, and released its first short sale data report on ZYXI on May 14, 2015. The report indicates a SqueezeTrigger price for all ZYXI shares shorted to be $0.66 per share. To view the report or get a more detailed description of the SqueezeTrigger and other indicators, go to http://www.buyins.net and enter "ZYXI" in the search box.

BUYINS.NET Issues Zynex (ZYXI) SqueezeTrigger Report
M2 - Fri May 15, 7:12AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Zynex, Inc. (OTC: ZYXI) after releasing the latest short sale data through May 14, 2015. The total aggregate number of shares shorted since August 2009 is approximately 7.26 million shares. Approximately 36.52% of daily trading volume is short selling. The SqueezeTrigger price for all ZYXI shares shorted is $0.66. A short squeeze is expected to begin when shares of ZYXI close above the $0.66 SqueezeTrigger price.

Zynex Announces First Quarter 2015 Results
Marketwired - Tue May 12, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics and compound pharmacy, announced today first quarter 2015 financial results.

Zynex Schedules First Quarter 2015 Earnings Release and Webcast
Marketwired - Wed May 06, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it will host the Company's first quarter investor webcast on Tuesday, May 12, 2015 at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time).

Zynex provides financial update
M2 - Thu Apr 16, 7:04AM CDT
Electrotherapy medical company Zynex (Other OTC:ZYXI) on Wednesday updated its turnaround of operations and financial estimate for the first and second quarters of 2015 as well as plans to release its first quarter earnings on or before 15 May 2015.

Zynex, Inc. Provides Financial Update
GlobeNewswire - Thu Apr 16, 6:39AM CDT
via PRWEB - Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and stroke rehabilitation, and transdermal pain creams, provides update on its turnaround of operations and financial estimate for the first and second quarters of 2015.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Beef 'O' Brady's Expands Into Tuscaloosa Market

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Employment Law Suit Hits ABC: Alleged Wage Violations

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...